BRAF and melanoma: Clinical trials are also ongoing using navitoclax in combination with osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in NSCLC (NCT02520778); sorafenib, a kinase inhibitor, in relapsed or refractory (R/R) solid tumors (NCT02143401); trametinib, a MEK inhibitor, in advanced or metastatic solid tumors (NCT02079740); and dabrafenib (a BRAF inhibitor)/trametinib in BRAF mutant melanoma (NCT01989585).